Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Exp Clin Endocrinol Diabetes ; 130(11): 714-722, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-36075228

RESUMO

PURPOSE: To investigate the clinical characteristics and associated factors of colonic polyps in patients with acromegaly. METHODS: Clinical characteristics and colonoscopy findings of 86 acromegaly patients who received treatment were retrospectively reviewed, and colonoscopy findings and the correlation with growth hormone (GH)-secreting pituitary adenoma (GHPA) volume and hormonal/metabolic levels were analyzed. RESULTS: The prevalence of colonic polyps in acromegaly patients was 40.7% and increased significantly with advanced age, especially in those ≥50 years. Multiple polyps (62.8%) and colonic polyps in the left colon (54.2%) were detected more frequently. Compared to acromegaly patients without polyps, those with polyps displayed higher insulin-like growth factor-1 × upper limit of normal (IGF-1×ULN) levels (P=0.03). IGF-1 levels and GHPA volumes in patients with polyps showed increasing trends, although the differences were not significant. GH levels were higher in patients with polyps of diameter ≤5 mm than those with polyps of diameter >5 mm (P=0.031). The univariate and multivariate logistic regression analysis revealed that GHPA volumes (OR: 1.09, 95% CI: 1.01-1.20; P=0.039) and IGF-1×ULN Q2 levels (OR: 6.51, 95% CI: 1.20-44.60; P=0.038) were independent factors for predicting the risk of colonic polyp occurrence in acromegaly patients. A nomogram was prepared to evaluate the risk of colonic polyps in acromegaly patients. CONCLUSION: The acromegalic patients are a population with a high prevalence of colonic polyps. GHPA volumes and IGF-1×ULN levels may be predictors of colonic polyp occurrence.


Assuntos
Acromegalia , Adenoma , Pólipos do Colo , Adenoma Hipofisário Secretor de Hormônio do Crescimento , Humanos , Pessoa de Meia-Idade , Pólipos do Colo/epidemiologia , Acromegalia/complicações , Acromegalia/epidemiologia , Fator de Crescimento Insulin-Like I/análise , Estudos Retrospectivos , Adenoma/complicações , Adenoma/epidemiologia
2.
Neurochem Res ; 42(2): 360-374, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27743286

RESUMO

Temporal lobe epilepsy (TLE) is one of the most refractory types of adult epilepsy, and treatment options remain unsatisfactory. Gastrodin (GAS), a phenolic glucoside used in Chinese herbal medicine and derived from Gastrodia elata Blume, has been shown to have remarkable anticonvulsant effects on various models of epilepsy in vivo. However, the mechanisms of GAS as an anticonvulsant drug remain to be established. By utilizing a combination of behavioral surveys, immunofluorescence and electrophysiological recordings, the present study characterized the anticonvulsant effect of GAS in a pilocarpine-induced status epilepticus (SE) rat model of TLE and explored the underlying cellular mechanisms. We found that GAS pretreatment effectively reduced the severity of SE in the acute phase of TLE. Moreover, GAS protected medial entorhinal cortex (mEC) layer III neurons from neuronal death and terminated the SE-induced bursting discharge of mEC layer II neurons from SE-experienced rats. Furthermore, the current study revealed that GAS prevented the pilocarpine-induced enhancement of Nav1.6 currents (persistent (INaP) and resurgent (INaR) currents), which were reported to play a critical role in the generation of bursting spikes. Consistent with this result, GAS treatment reversed the expression of Nav1.6 protein in SE-experienced EC neurons. These results suggest that the inhibition of Nav1.6 sodium currents may be the underlying mechanism of GAS's anticonvulsant properties.


Assuntos
Álcoois Benzílicos/uso terapêutico , Epilepsia do Lobo Temporal/tratamento farmacológico , Glucosídeos/uso terapêutico , Canal de Sódio Disparado por Voltagem NAV1.6/fisiologia , Pilocarpina/toxicidade , Bloqueadores dos Canais de Sódio/uso terapêutico , Estado Epiléptico/tratamento farmacológico , Animais , Álcoois Benzílicos/farmacologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Epilepsia do Lobo Temporal/fisiopatologia , Glucosídeos/farmacologia , Masculino , Ratos , Ratos Sprague-Dawley , Índice de Gravidade de Doença , Bloqueadores dos Canais de Sódio/farmacologia , Estado Epiléptico/induzido quimicamente , Estado Epiléptico/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA